OPIANT PHARMACEUTICALS INC (OPNT) Fundamental Analysis & Valuation

NASDAQ:OPNT • US6837501039

Current stock price

20.65 USD
-0.12 (-0.58%)
At close:
20.75 USD
+0.1 (+0.48%)
After Hours:

This OPNT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. OPNT Profitability Analysis

1.1 Basic Checks

  • In the past year OPNT has reported negative net income.
  • OPNT had a negative operating cash flow in the past year.
OPNT Yearly Net Income VS EBIT VS OCF VS FCFOPNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 10M -10M -20M

1.2 Ratios

  • The profitability ratios for OPNT are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OPNT Yearly ROA, ROE, ROICOPNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200 -400

1.3 Margins

  • With an excellent Gross Margin value of 82.70%, OPNT belongs to the best of the industry, outperforming 89.59% of the companies in the same industry.
  • OPNT's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for OPNT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.2%
GM growth 5YN/A
OPNT Yearly Profit, Operating, Gross MarginsOPNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. OPNT Health Analysis

2.1 Basic Checks

  • OPNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OPNT has more shares outstanding than it did 1 year ago.
  • OPNT has a better debt/assets ratio than last year.
OPNT Yearly Shares OutstandingOPNT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 1M 2M 3M 4M
OPNT Yearly Total Debt VS Total AssetsOPNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -1.19, we must say that OPNT is in the distress zone and has some risk of bankruptcy.
  • OPNT's Altman-Z score of -1.19 is in line compared to the rest of the industry. OPNT outperforms 46.61% of its industry peers.
  • OPNT has a Debt/Equity ratio of 0.60. This is a neutral value indicating OPNT is somewhat dependend on debt financing.
  • OPNT has a worse Debt to Equity ratio (0.60) than 67.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -1.19
ROIC/WACCN/A
WACC9%
OPNT Yearly LT Debt VS Equity VS FCFOPNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 10M 20M 30M 40M

2.3 Liquidity

  • OPNT has a Current Ratio of 5.48. This indicates that OPNT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of OPNT (5.48) is better than 61.09% of its industry peers.
  • A Quick Ratio of 5.48 indicates that OPNT has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.48, OPNT is doing good in the industry, outperforming 61.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48
OPNT Yearly Current Assets VS Current LiabilitesOPNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. OPNT Growth Analysis

3.1 Past

  • OPNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13200.00%.
  • OPNT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.13%.
  • Measured over the past years, OPNT shows a very strong growth in Revenue. The Revenue has been growing by 37.00% on average per year.
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-442.86%
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y37%
Sales Q2Q%-98.94%

3.2 Future

  • Based on estimates for the next years, OPNT will show a very strong growth in Earnings Per Share. The EPS will grow by 66.96% on average per year.
  • Based on estimates for the next years, OPNT will show a quite strong growth in Revenue. The Revenue will grow by 17.51% on average per year.
EPS Next Y-2455.56%
EPS Next 2Y-255.39%
EPS Next 3Y66.96%
EPS Next 5YN/A
Revenue Next Year-80.95%
Revenue Next 2Y-11.14%
Revenue Next 3Y17.51%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OPNT Yearly Revenue VS EstimatesOPNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OPNT Yearly EPS VS EstimatesOPNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. OPNT Valuation Analysis

4.1 Price/Earnings Ratio

  • OPNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OPNT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OPNT Price Earnings VS Forward Price EarningsOPNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OPNT Per share dataOPNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • OPNT's earnings are expected to grow with 66.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-255.39%
EPS Next 3Y66.96%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OPNT Dividend Analysis

5.1 Amount

  • OPNT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

OPNT Fundamentals: All Metrics, Ratios and Statistics

OPIANT PHARMACEUTICALS INC

NASDAQ:OPNT (3/1/2023, 8:00:03 PM)

After market: 20.75 +0.1 (+0.48%)

20.65

-0.12 (-0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.97%
Ins Owner Change0%
Market Cap108.80M
Revenue(TTM)22.34M
Net Income(TTM)-33.09M
Analysts45.71
Price Target21.42 (3.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-45.98%
Min EPS beat(2)-65.91%
Max EPS beat(2)-26.05%
EPS beat(4)1
Avg EPS beat(4)230.99%
Min EPS beat(4)-162.52%
Max EPS beat(4)1178.43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-56.68%
Min Revenue beat(2)-95.37%
Max Revenue beat(2)-17.98%
Revenue beat(4)1
Avg Revenue beat(4)-34.27%
Min Revenue beat(4)-95.37%
Max Revenue beat(4)2.01%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.33%
PT rev (3m)-2.33%
EPS NQ rev (1m)40.78%
EPS NQ rev (3m)40.78%
EPS NY rev (1m)8.77%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)63.64%
Revenue NQ rev (3m)63.64%
Revenue NY rev (1m)-2.9%
Revenue NY rev (3m)-44.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.87
P/FCF N/A
P/OCF N/A
P/B 5.31
P/tB 5.31
EV/EBITDA N/A
EPS(TTM)-6.55
EYN/A
EPS(NY)-3.4
Fwd EYN/A
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS4.24
BVpS3.89
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.7%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.2%
GM growth 5YN/A
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z -1.19
F-Score2
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)180.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-442.86%
EPS Next Y-2455.56%
EPS Next 2Y-255.39%
EPS Next 3Y66.96%
EPS Next 5YN/A
Revenue 1Y (TTM)-49.13%
Revenue growth 3Y50.64%
Revenue growth 5Y37%
Sales Q2Q%-98.94%
Revenue Next Year-80.95%
Revenue Next 2Y-11.14%
Revenue Next 3Y17.51%
Revenue Next 5YN/A
EBIT growth 1Y-1195.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-347.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-339.4%
OCF growth 3YN/A
OCF growth 5YN/A

OPIANT PHARMACEUTICALS INC / OPNT Fundamental Analysis FAQ

What is the fundamental rating for OPNT stock?

ChartMill assigns a fundamental rating of 3 / 10 to OPNT.


Can you provide the valuation status for OPIANT PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to OPIANT PHARMACEUTICALS INC (OPNT). This can be considered as Overvalued.


Can you provide the profitability details for OPIANT PHARMACEUTICALS INC?

OPIANT PHARMACEUTICALS INC (OPNT) has a profitability rating of 0 / 10.


Can you provide the financial health for OPNT stock?

The financial health rating of OPIANT PHARMACEUTICALS INC (OPNT) is 4 / 10.